NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

longfellow95, I agree with everything you said.

The only thing I would add is, I also believe that after DCVax-L is approved, and it becomes a core / foundational part of the new standard of care (SOC) to treat both ndGBM and rGBM, adjuvant DCVax-L will be combined with a neoadjuvant PD-1 inhibitor (Keytruda / Pembrolizumab) treatment.

The PD-1 inhibitor will be given to the GBM patients prior to their tumor resection surgery. Then, after the GBM patients recover from their tumor resection surgery, they will receive an adjuvant treatment of DCVax-L.